Chao (Brook) Wu

CEO, Golden Age Health China

More than 30 years in China's pharmaceutical industry, across multinational, joint-venture and local companies and healthcare investment.

LinkedIn profile

Biography

Brook Wu leads Golden Age Health's business in China as Chief Executive Officer of Golden Age Health (Shanghai). He joined in 2025 to build the company's commercialization platform for rare disease and specialty medicines in China, covering medical affairs, market access, patient advocacy and partner management.

Under his leadership the China team supported access to Raxone for LHON through the Hainan Boao Lecheng pilot zone, reaching 100 patients in seven months, and took on the commercialization of ZTALMY for CDKL5 deficiency disorder in mainland China.

Before Golden Age Health, Brook was Managing Director and Partner at Vigintillion Capital, investing in healthcare, pharmaceutical and medical device companies. Earlier he was Vice General Manager of Hemony Pharmaceuticals, responsible for strategy, business development, regulatory affairs, marketing and R&D, and Director of Strategic Planning and Business Development at Abbott and at Mundipharma, with a focus on M&A in China. He held strategic alliance and portfolio planning roles at MSD China, and began at Pfizer China, where he rose to Head of Marketing for the Specialty and Anti-Infective business unit.

“When patients are satisfied, physicians are reassured, and partners are delighted, success becomes inevitable.”

Chao (Brook) Wu

Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.